January 4, 2016
Implementation of the Drug Supply Chain Security Act (DSCSA), efforts to mitigate Rx Drug Abuse, Tax Reform and Globalization will be top priorities for HDMA in 2016, according to HDMA President and CEO John M. Gray. Mr. Gray highlighted these issues in Chain Drug Review’s annual "Pharmacy Outlook" feature, published on January 4.
In his column, Gray notes, "A constant theme in the pharmaceutical distribution industry is change. This year — a presidential election year — will be no exception, full of transformation and transitions as well as unexpected challenges and opportunities. However, the true lasting impact of this change will be measured by how an industry adapts to it … in 2016 and beyond, HDMA is committed to building for its members, and the industry at large, a solid foundation for the next generation of supply chain leaders to innovate and thrive."
HDA is the national association representing primary healthcare distributors, the vital link between the nation’s pharmaceutical manufacturers and healthcare providers. Each business day, HDA member companies ensure that over 15 million prescription medicines and healthcare products are delivered safely and efficiently to more than 200,000 pharmacies, hospitals, long-term care facilities, clinics and others nationwide. HDA and its members work daily to provide value and achieve cost savings, an estimated $42 billion each year to our nation’s healthcare system.